Modification of hTERT Expression for the Treatment of Solid Tumors

Technology #ua17-199

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Laurence Hurley
Professor, Pharmacology & Toxicology
Andrew Kraft
Professor, Medicine
Jin Song
assistant professor, Cellular & Molecular Medicine
Vijay Gokhale
Senior Research Scientist, BIO5
Managed By
Rakhi Gibbons
Asst. Director, Life Sciences (520) 626-6695

Title: Modification of hTERT Expression for the Treatment of Solid Tumors

 

Invention: This invention is a synthetic compound intended to selectively kill hTERT prostate cancer cells through targeting the G-quadruplex, leaving normal prostate cells intact.

 

Background: Studies predict that a total of 27,000 Americans will die from Metastatic Prostate Cancer (PCa). PCa is commonly treated with a combination of hormone therapies and chemotherapy. Unfortunately hormone therapy loses effectiveness over time. This invention aims to satisfy the unmet need for long term treatment of cancer types containing hTERT cells.

 

Applications:

  • Cancer treatment (hormone and chemotherapy)

 

Advantages:

  • 10,000 times more effective on Taxotere resistant prostate cancer cells

 

Licensing Manager:

Rakhi Gibbons

RakhiG@tla.arizona.edu

(520) 626-6695